معرفی
Haider Sami is a researcher at the University of Vienna, affiliated with the Faculty of Life Sciences and the Department of Pharmaceutical Sciences. He works in the Macromolecular Cancer Therapeutics (MMCT) laboratory under Professor Manfred Ogris, focusing on RNA-based therapeutics and nanocarrier delivery systems. His research addresses critical challenges in splice-switching oligonucleotide (SSO) delivery, particularly regarding endosomal escape, nuclear targeting, and systemic biodistribution.
Haider Sami's research expertise spans nanocarrier design for RNA splicing modulation, with a particular emphasis on redox-responsive polymers like disulfide cross-linked polyethylenimine (cLPEI). He has pioneered methods for accelerated endosomal release and hepatic splice correction, validated through transgenic mouse models expressing split-luciferase reporters. His work demonstrates that cLPEI-SSO polyplexes significantly improve in vivo bioavailability while reducing renal excretion and enhancing tumor accumulation.
Key research contributions include disulfide crosslinking strategies for endosomal escape enhancement, one-step nanoparticle synthesis using Brij-linkers, and spatiotemporal delivery tracking via NIR fluorescence imaging and X-ray computed tomography. These studies have direct implications for monogenic disease therapies and cancer treatment applications.
Haider Sami has authored 24 publications since 2014, with recent work (2023-2025) emphasizing biocompatible delivery systems, quantitative biodistribution analysis, and functional protein restoration in multiple organ systems including liver, lung, kidney, and bladder.
